IN2014DN10899A - - Google Patents
Info
- Publication number
- IN2014DN10899A IN2014DN10899A IN10899DEN2014A IN2014DN10899A IN 2014DN10899 A IN2014DN10899 A IN 2014DN10899A IN 10899DEN2014 A IN10899DEN2014 A IN 10899DEN2014A IN 2014DN10899 A IN2014DN10899 A IN 2014DN10899A
- Authority
- IN
- India
- Prior art keywords
- mir
- abundance
- inhibiting
- expression
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261662772P | 2012-06-21 | 2012-06-21 | |
US201361780352P | 2013-03-13 | 2013-03-13 | |
PCT/US2013/046960 WO2013192486A1 (fr) | 2012-06-21 | 2013-06-21 | Inhibiteurs de la famille mir-15 de micro-arn |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN10899A true IN2014DN10899A (fr) | 2015-09-11 |
Family
ID=49769409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN10899DEN2014 IN2014DN10899A (fr) | 2012-06-21 | 2013-06-21 |
Country Status (17)
Country | Link |
---|---|
US (1) | US9163235B2 (fr) |
EP (1) | EP2863956A4 (fr) |
JP (1) | JP2015525081A (fr) |
KR (1) | KR20150036140A (fr) |
CN (1) | CN104540527A (fr) |
AR (1) | AR091539A1 (fr) |
AU (1) | AU2013277033A1 (fr) |
BR (1) | BR112014032239A2 (fr) |
CA (1) | CA2876105A1 (fr) |
EA (1) | EA201590070A1 (fr) |
HK (1) | HK1209621A1 (fr) |
IN (1) | IN2014DN10899A (fr) |
MD (1) | MD20150006A2 (fr) |
MX (1) | MX2014015641A (fr) |
SG (1) | SG11201408460UA (fr) |
TW (1) | TW201406774A (fr) |
WO (1) | WO2013192486A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013192576A2 (fr) | 2012-06-21 | 2013-12-27 | Miragen Therapeutics | Inhibiteurs à base d'oligonucléotides comprenant un motif d'acide nucléique bloqué |
WO2014145356A1 (fr) | 2013-03-15 | 2014-09-18 | MiRagen Therapeutics, Inc. | Nucléosides bicycliques pontés |
US10443044B2 (en) | 2014-04-17 | 2019-10-15 | Ips Heart | Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds |
AU2015301221B2 (en) | 2014-08-04 | 2020-07-02 | MiRagen Therapeutics, Inc. | Inhibitors of MYH7B and uses thereof |
KR20170033439A (ko) | 2014-08-07 | 2017-03-24 | 레굴루스 테라퓨틱스 인크 | 대사 장애에 대한 마이크로rna의 표적화 |
CN107636003A (zh) | 2015-01-20 | 2018-01-26 | 米拉根医疗股份有限公司 | miR‑92抑制剂及其用途 |
WO2017219170A1 (fr) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | Construction et application d'un vecteur lentiviral pour l'inhibition spécifique de l'expression de miarn-29a humain et de mir-424 humain |
JP2019535839A (ja) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | 治療剤の送達のためのエクソソーム |
CN106692175A (zh) * | 2016-12-26 | 2017-05-24 | 大连医科大学附属第二医院 | miR‑665‑3p抑制物在制备防治缺血再灌注损伤药物中的应用 |
US10941403B2 (en) | 2018-04-02 | 2021-03-09 | Oregon Health & Science University | Microrna inhibitors as anti-cancer therapeutics |
WO2021020412A1 (fr) | 2019-07-30 | 2021-02-04 | 塩野義製薬株式会社 | Médicament à base d'acide nucléique ciblant le murf1 |
CN116438305A (zh) * | 2020-07-23 | 2023-07-14 | 法兰克福大学 | 用于治疗心力衰竭的miRNA的组合抑制 |
CN113599540B (zh) * | 2021-05-27 | 2023-05-23 | 山西医科大学 | miRNA-195-5p在制备抑制或降低麦芽酚铝所致神经细胞损伤的试剂中的应用 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2462144C (fr) | 2001-09-28 | 2016-09-20 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Molecules de micro-arn |
PT1504126E (pt) | 2002-05-03 | 2014-06-02 | Univ Duke | Um método para regular a expressão génica |
US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
AU2003291433B2 (en) | 2002-11-13 | 2008-05-22 | Thomas Jefferson University | Compositions and methods for cancer diagnosis and therapy |
WO2004058052A2 (fr) | 2002-12-20 | 2004-07-15 | Applera Corporation | Polymorphismes genetiques associes a l'infarctus du myocarde, techniques de detection et utilisations de ceux-ci |
KR20050115231A (ko) | 2003-02-10 | 2005-12-07 | 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 | 포유동물 세포의 조절 |
WO2005017111A2 (fr) | 2003-07-15 | 2005-02-24 | The Trustees Of The University Of Pennsylvania | Procedes et systemes d'identification de cibles de microarn et de synthetisation de nouveaux microarn et leurs utilisations |
WO2005013901A2 (fr) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants |
WO2005047505A2 (fr) | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Techniques et produits d'expression de micro arn |
WO2005017145A1 (fr) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | Methode d'identification reelle ou presumee d'un gene soumis a une regulation commandee par un arn fonctionnel et utilisation de cette methode |
JPWO2005028648A1 (ja) | 2003-09-22 | 2007-11-15 | 愛知県 | リンパ腫の病型および予後診断方法 |
CA2539654A1 (fr) | 2003-10-14 | 2005-05-06 | Novartis Ag | Jeu ordonne de microechantillons oligonucleotidiques |
AU2004291102A1 (en) | 2003-11-13 | 2005-06-02 | Board Of Regents, The University Of Texas System | Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure |
EP1713916A4 (fr) | 2003-12-15 | 2007-12-12 | College Medicine Pochon Cha Univ Ind Acad Coop Found | Molecules d'arnmi isolees d'une cellule souche embryonnaire humaine |
EP2295604B1 (fr) | 2004-02-09 | 2015-04-08 | Thomas Jefferson University | Diagnostic et traitement de cancers à l'aide de microARN présent dans ou au voisinage de caractéristiques chromosomiques associées aux cancers |
US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
CA2556435C (fr) | 2004-02-13 | 2014-08-12 | The Rockefeller University | Molecules d'oligonucleotides anti-microarn |
US8088902B2 (en) | 2004-04-05 | 2012-01-03 | The Rockefeller University | DNA virus microRNA and methods for inhibiting same |
US20050260648A1 (en) | 2004-04-06 | 2005-11-24 | Huffel Christophe V | Method for the determination of cellular transcriptional |
US20060134639A1 (en) | 2004-04-06 | 2006-06-22 | Huffel Christophe V | Method for the determination of cellular transcriptional regulation |
CA2562390C (fr) | 2004-04-07 | 2014-12-02 | Exiqon A/S | Methodes permettant de quantifier des micro arn et petits arn interferants |
EP2290071B1 (fr) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Procédés et compositions impliquant du microARN |
WO2006020768A2 (fr) | 2004-08-10 | 2006-02-23 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides chimiquement modifies |
US7893034B2 (en) | 2004-09-02 | 2011-02-22 | Yale University | Regulation of oncogenes by microRNAs |
FR2877350B1 (fr) | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE |
EP2281888B1 (fr) | 2004-11-12 | 2015-01-07 | Asuragen, Inc. | Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi |
WO2006063356A1 (fr) | 2004-12-10 | 2006-06-15 | Isis Phamaceuticals, Inc. | Regulation du controle epigenetique de l'expression genique |
US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
WO2006071884A2 (fr) | 2004-12-27 | 2006-07-06 | The Regents Of The University Of Michigan | Agents therapeutiques a base d'oligonucleotides |
EP1959012A3 (fr) | 2004-12-29 | 2009-12-30 | Exiqon A/S | Nouvelles compositions oligonucléotides et séquences de sonde utiles pour la détection et l'analyse de micro ARN et leurs ARN cibles |
US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
US20070065840A1 (en) | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
JP2006292367A (ja) | 2005-04-05 | 2006-10-26 | Mitsubishi Rayon Co Ltd | miRNA検出用マイクロアレイ |
US20090214477A1 (en) | 2005-04-15 | 2009-08-27 | Cenix Bioscience Gmbh | Human Marker Genes and Agents for Diagnosis, Treatment and Prophylaxis of Cardiovascular Disorders and Artherosclerosis |
WO2006111512A1 (fr) | 2005-04-19 | 2006-10-26 | Basf Plant Science Gmbh | Methodes ameliorees controlant une expression genique |
DK2002003T3 (en) | 2005-05-27 | 2016-03-21 | Ospedale San Raffaele Srl | Gene vector comprising miRNA |
EP1896587A2 (fr) | 2005-05-31 | 2008-03-12 | Cold Spring Harbor Laboratory | METHODE DE PRODUCTION DE MICRO-ARNs |
US20070054287A1 (en) | 2005-05-31 | 2007-03-08 | Applera Corporation | Method for identifying medically important cell populations using micro rna as tissue specific biomarkers |
WO2006133022A2 (fr) | 2005-06-03 | 2006-12-14 | The Johns Hopkins University | Compositions et procedes pour diminuer l'expression de microarn pour le traitement de la neoplasie |
CA2618995A1 (fr) | 2005-08-10 | 2007-02-22 | The Rockefeller University | Oligonucleotides chimiquement modifies pouvant etre employes dans la modulation de micro-arn et applications |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
CN101426912A (zh) | 2005-08-17 | 2009-05-06 | 瑟纳治疗公司 | 介导rna干扰的化学修饰短干扰核酸分子 |
ES2523989T3 (es) | 2005-09-12 | 2014-12-03 | The Ohio State University Research Foundation | Composiciones para la terapia de cánceres asociados con BCL2 |
US20070092882A1 (en) | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
AU2006315099C1 (en) | 2005-11-21 | 2013-01-10 | Johnson & Johnson Research Pty Limited | Multitargeting interfering RNAs and methods of their use and design |
US20070259827A1 (en) | 2006-01-25 | 2007-11-08 | University Of Massachusetts | Compositions and methods for enhancing discriminatory RNA interference |
JP2009524430A (ja) | 2006-01-26 | 2009-07-02 | ユニバーシティ オブ マサチューセッツ | 治療的使用のためのrna干渉剤 |
WO2007092181A2 (fr) | 2006-01-26 | 2007-08-16 | Unversity Of Massachusetts | Compositions et méthodes permettant de moduler la répression traductionnelle |
EP2388328A1 (fr) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Composés oligomères et compositions pour une utilisation dans la modulation de micro ARN |
EP1986697B1 (fr) | 2006-02-17 | 2016-06-29 | GE Healthcare Dharmacon, Inc. | Compositions et procédés permettant l'inhibition de silençage de gènes par l'interférence arn |
EP2522750A1 (fr) | 2006-03-02 | 2012-11-14 | The Ohio State University | Profil d'expression de micro-ARN associé au cancer du pancréas |
CA3042781C (fr) * | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Composition pharmaceutique comprenant des oligonucleotides antisens anti-microarn |
US20080220423A1 (en) | 2006-05-19 | 2008-09-11 | Soren Moller | Oligonucleotide probes useful for detection and analysis of microRNA precursors |
US9200275B2 (en) | 2006-06-14 | 2015-12-01 | Merck Sharp & Dohme Corp. | Methods and compositions for regulating cell cycle progression |
US20090307788A1 (en) | 2006-06-19 | 2009-12-10 | Kobenhavns Universitet | Ribozyme mediated stabilization of polynucleotides |
EP2054529B1 (fr) | 2006-08-25 | 2014-03-26 | Duke University | PROCÉDÉS D'IDENTIFICATION IN VIVO DE CIBLES D'ARNm ENDOGÈNE DE MICRO ARN |
EP2145001A2 (fr) | 2006-09-19 | 2010-01-20 | Asuragen, Inc. | Gènes régulés mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p et voies de signalisation utiles comme cibles dans une intervention thérapeutique |
US20090306181A1 (en) | 2006-09-29 | 2009-12-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
EP2476762B1 (fr) | 2006-10-09 | 2014-01-08 | Julius-Maximilians-Universität Würzburg | Micro-ARN (miARN) pour le diagnostic et le traitement de maladies cardiaques |
WO2008147430A2 (fr) | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Constructions vectorielles d'arn interférant multicible formaté par micro-arn et leurs procédés d'utilisation |
CA2681568C (fr) | 2006-11-23 | 2019-01-08 | Querdenker Aps | Oligonucleotides pour moduler l'activite d'arn cible |
EP2104736B1 (fr) | 2006-12-08 | 2011-11-23 | Asuragen, INC. | Gènes et voies régulés par mir-126 comme cibles d'intervention thérapeutique |
CA2671302A1 (fr) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Genes et voies regules par miarn comme cibles d'intervention therapeutique |
CN101675165A (zh) | 2006-12-08 | 2010-03-17 | 奥斯瑞根公司 | Let-7微小rna的功能和靶标 |
CA2671294A1 (fr) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Genes et voies genetiques regules par mir-21 utilises en tant que cibles pour une intervention therapeutique |
US20090137504A1 (en) | 2006-12-21 | 2009-05-28 | Soren Morgenthaler Echwald | Microrna target site blocking oligos and uses thereof |
EP3536788A1 (fr) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Oligos de blocage de sites cibles de microarn et leurs utilisations |
US20090175827A1 (en) | 2006-12-29 | 2009-07-09 | Byrom Mike W | miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20080287383A1 (en) | 2007-03-02 | 2008-11-20 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
US9043994B2 (en) | 2007-03-13 | 2015-06-02 | Massachusetts Institute Of Technology | Cre-lox based gene knockdown constructs and methods of use thereof |
US8288358B2 (en) | 2007-03-26 | 2012-10-16 | Newcastle Innovation Ltd. | Therapeutic targets and molecules |
US9353368B2 (en) | 2007-05-23 | 2016-05-31 | Ge Healthcare Dharmacon, Inc. | Micro-RNA scaffolds and non-naturally occurring micro-RNAs |
WO2009012263A2 (fr) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Micro-arn à spécificité cellulaire et compositions et utilisations de ces micro-arn |
CA2693031A1 (fr) | 2007-07-18 | 2009-01-22 | The Regents Of The University Colorado | Expression differentielle de microarn de curs humains non insuffisants contre des coeurs humains insuffisants |
US20090092980A1 (en) | 2007-07-20 | 2009-04-09 | Christoph Arenz | miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES |
WO2009044895A1 (fr) | 2007-10-03 | 2009-04-09 | Kyowa Hakko Kirin Co., Ltd. | Composition inhibant l'expression d'un gène cible |
ES2463665T3 (es) | 2007-10-04 | 2014-05-28 | Stella Aps | Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C |
CA2704056A1 (fr) | 2007-10-29 | 2009-05-07 | University Of Massachusetts | Nanoparticules encapsulees pour l'administration d'acides nucleiques |
WO2009058818A2 (fr) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprenant un micro-arn et procédés pour leur utilisation dans la régulation du remodelage cardiaque |
WO2009062169A2 (fr) | 2007-11-09 | 2009-05-14 | The Board Of Regents Of The University Of Texas System | Micro-arn de la famille mir-15 modulant la survie de cardiomyocytes et la réparation cardiaque |
US8361980B2 (en) | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
WO2009121031A1 (fr) | 2008-03-27 | 2009-10-01 | Vascular Biosciences, Inc. | Procédé d'identification de nouveaux candidats thérapeutiques via l'analyse d'expression génique dans les maladies d'origine vasculaire |
EP2105145A1 (fr) | 2008-03-27 | 2009-09-30 | ETH Zürich | Procédé pour la libération spécifique dans les muscles d'oligonucléotides conjugués avec des lipides |
US20090326049A1 (en) | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
US20100113284A1 (en) | 2008-04-04 | 2010-05-06 | Alexander Aristarkhov | Small interfering rna (sirna) target site blocking oligos and uses thereof |
US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
AU2009256243A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small RNA targeting of gene promoters |
WO2010036939A2 (fr) | 2008-09-26 | 2010-04-01 | University Of Southern California | Système d'expression synergiste de petits éléments d'arn fonctionnels multiples |
WO2010048585A2 (fr) | 2008-10-24 | 2010-04-29 | Isis Pharmaceuticals, Inc. | Composés oligomères et méthodes |
WO2010126355A1 (fr) | 2009-04-29 | 2010-11-04 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Moyens et procédés pour contrecarrer, prévenir et/ou déterminer une insuffisance cardiaque ou un risque d'insuffisance cardiaque |
CN102803284B (zh) | 2009-06-08 | 2015-11-25 | 米拉根医疗公司 | 用于miRNA抑制剂和模拟物的化学修饰基序 |
-
2013
- 2013-06-19 US US13/921,537 patent/US9163235B2/en not_active Expired - Fee Related
- 2013-06-21 JP JP2015518597A patent/JP2015525081A/ja active Pending
- 2013-06-21 WO PCT/US2013/046960 patent/WO2013192486A1/fr active Application Filing
- 2013-06-21 AU AU2013277033A patent/AU2013277033A1/en not_active Abandoned
- 2013-06-21 CA CA2876105A patent/CA2876105A1/fr not_active Abandoned
- 2013-06-21 MX MX2014015641A patent/MX2014015641A/es unknown
- 2013-06-21 MD MDA20150006A patent/MD20150006A2/ro not_active Application Discontinuation
- 2013-06-21 TW TW102122289A patent/TW201406774A/zh unknown
- 2013-06-21 EP EP13806131.2A patent/EP2863956A4/fr not_active Withdrawn
- 2013-06-21 SG SG11201408460UA patent/SG11201408460UA/en unknown
- 2013-06-21 CN CN201380039961.7A patent/CN104540527A/zh active Pending
- 2013-06-21 KR KR1020157001535A patent/KR20150036140A/ko not_active Application Discontinuation
- 2013-06-21 BR BR112014032239A patent/BR112014032239A2/pt not_active IP Right Cessation
- 2013-06-21 IN IN10899DEN2014 patent/IN2014DN10899A/en unknown
- 2013-06-21 EA EA201590070A patent/EA201590070A1/ru unknown
- 2013-06-24 AR ARP130102219 patent/AR091539A1/es unknown
-
2015
- 2015-10-22 HK HK15110356.0A patent/HK1209621A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN104540527A (zh) | 2015-04-22 |
AU2013277033A1 (en) | 2015-01-22 |
EA201590070A1 (ru) | 2015-04-30 |
MX2014015641A (es) | 2015-07-14 |
CA2876105A1 (fr) | 2013-12-27 |
TW201406774A (zh) | 2014-02-16 |
BR112014032239A2 (pt) | 2017-08-01 |
EP2863956A1 (fr) | 2015-04-29 |
WO2013192486A1 (fr) | 2013-12-27 |
KR20150036140A (ko) | 2015-04-07 |
SG11201408460UA (en) | 2015-01-29 |
EP2863956A4 (fr) | 2016-01-20 |
JP2015525081A (ja) | 2015-09-03 |
HK1209621A1 (en) | 2016-04-08 |
AR091539A1 (es) | 2015-02-11 |
US20130345288A1 (en) | 2013-12-26 |
MD20150006A2 (ro) | 2015-06-30 |
US9163235B2 (en) | 2015-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN10899A (fr) | ||
MX2013005875A (es) | Inhibidores de microarn que comprenden nucleotidos bloqueados. | |
MX2019012252A (es) | Composiciones y metodos para inhibir la expresion del gen alas1. | |
UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
PH12017501501A1 (en) | Compositions and methods for inhibiting expression of tmprss6 gene | |
MX2021015290A (es) | Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3). | |
NZ797319A (en) | Modified rnai agents | |
MX2019006413A (es) | Composiciones de arni de serpinc1 y metodos de uso de las mismas. | |
MX355408B (es) | Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado. | |
UA115652C2 (uk) | Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21 | |
WO2012142313A8 (fr) | Inhibiteurs de micro-arn et leurs utilisations dans des maladies | |
WO2012024396A3 (fr) | Compositions et méthodes permettant d'administrer des molécules d'acide nucléique et de traiter un cancer | |
MX2022001017A (es) | Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1). | |
IN2014CN03921A (fr) | ||
AR083445A1 (es) | siARN CONTRA LA FIBROSIS | |
MX368084B (es) | siRNA Y SU USO EN LA PREPARACIÓN DE UN MEDICAMENTO PARA USARSE EN UN MÉTODO PARA EL TRATAMIENTO DE UN TRANSTORNO OCULAR. | |
PL398796A1 (pl) | Zastosowanie czasteczek miRNA oraz antagomiru dla miRNA w diagnostyce, zapobieganiu i leczeniu stwardnienia rozsianego | |
NZ776080A (en) | Modified rnai agents | |
NZ728207A (en) | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |